Trials / Completed
CompletedNCT01350141
A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins
A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | An infusion lasting approximately 60 minutes |
| DRUG | PF-04950615 (RN316) | An infusion lasting approximately 60 minutes |
| DRUG | PF-04950615 (RN316) | An infusion lasting approximately 60 minutes |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2012-04-01
- Completion
- 2012-06-01
- First posted
- 2011-05-09
- Last updated
- 2017-11-08
- Results posted
- 2017-11-08
Locations
35 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01350141. Inclusion in this directory is not an endorsement.